Biomarkers of Disorders of the Nervous System
In spite of all the advances in neurology, there are serious deficiencies in our understanding of the pathomechanism of several neurological disorders as well as our ability to diagnose and treat these disorders. Biotechnologies are being increasingly applied in neurology to address some of these deficiencies. Novel biomarker identification for neurological disorders will address the current shortcomings in their diagnosis and therapeutics.
Related Conference of Biomarkers of Disorders of the Nervous System
October 30-31, 2025
20th World Congress on Biomarkers, Cancer Therapy & Clinical Research
Rome, Italy
April 27-28, 2026
7th Annual Congress on Biosimilars and Future Biotherapeutics
Paris, Aland Islands
June 29-30, 2026
41st International Conference on Next-Gen Biotechnology and Applications
Aix-en-Provence, France
Biomarkers of Disorders of the Nervous System Conference Speakers
Recommended Sessions
- Biomarkers & Next-Generation Sequencing
- Biomarkers based on epidemiological investigations
- Biomarkers for Cancer Diagnosis
- Biomarkers in Drug discovery and development
- Biomarkers of Cardiovascular disorders
- Discovery of new biomarkers/validation/technologies
- Entrepreneur Investments Meet
- Imaging Technologies and Diagnostic tests of Biomarkers
- Biomarkers for Early Diagnosis and Prognosis
- Biomarkers for non-cancerous diseases
- Biomarkers in Diagnosis: Challenges and Approaches
- Biomarkers in Disease Treatment
- Biomarkers in Immune-Oncology
- Biomarkers of Disorders of the Nervous System
- Biomarkers: Validation & Verification
- Clinical and Biomedical Engineering
- Clinical Research & Biomarkers
- Genomic Biomarkers in Clinical Development
Related Journals
Are you interested in
- 3D Bioprinting & Regenerative Medicine - Biotechnology- 2025 (France)
- Advancements in Biosimilar Development Technologies - Biosimilars 2026 (France)
- Advances in Genomic Biotechnology - Biotechnology 2025 (Spain)
- AI in Drug Discovery - Biotechnology- 2025 (France)
- AI in Vaccine Development - Biotechnology- 2025 (France)
- AI-Powered Precision Medicine - Biotechnology- 2025 (France)
- Artificial Intelligence and Digital Tools in Biotherapeutics - Biosimilars 2026 (France)
- Bio-Cybernetics & Smart Implants - Biotechnology- 2025 (France)
- Biobetters: The Next Generation of Biologics - Biosimilars 2026 (France)
- Bioethics in Biotechnology 5.0 - Biotechnology- 2025 (France)
- Bioinformatics & Big Data - Biotechnology- 2025 (France)
- Biomedical Biotechnology - Biotechnology 2025 (Spain)
- Biopharmaceuticals and Biosimilars - Biotechnology 2025 (Spain)
- Biosimilar Market Access and Reimbursement Policies - Biosimilars 2026 (France)
- Biosimilars in Oncology and Autoimmune Diseases - Biosimilars 2026 (France)
- Biosimilars in Rare and Orphan Diseases - Biosimilars 2026 (France)
- Biotechnology and Global Health - Biotechnology 2025 (Spain)
- Biotechnology in Agriculture - Biotechnology 2025 (Spain)
- Biotechnology in Space - Biotechnology- 2025 (France)
- Blockchain for Biotech Data Security - Biotechnology- 2025 (France)
- Brain-Computer Interfaces & Neurobiotech - Biotechnology- 2025 (France)
- Clinical Trials & Comparability Studies for Biosimilars - Biosimilars 2026 (France)
- Collaborative Models in Biosimilar Development - Biosimilars 2026 (France)
- Computational and Systems Biology - Biotechnology 2025 (Spain)
- Cost-Effectiveness and Health Economics of Biosimilars - Biosimilars 2026 (France)
- CRISPR & Beyond - Biotechnology- 2025 (France)
- Environmental Biotechnology - Biotechnology 2025 (Spain)
- Evolving Trends and Innovations in Biosimilar Development and Access - Biosimilars 2026 (France)
- Formulation and Delivery Systems for Biologics - Biosimilars 2026 (France)
- Future Biotherapeutics: Cell and Gene Therapies - Biosimilars 2026 (France)
- Future of AgriTech - Biotechnology- 2025 (France)
- Future of Monoclonal Antibodies and Fusion Proteins - Biosimilars 2026 (France)
- Future Trends in Biotechnology - Biotechnology 2025 (Spain)
- Global Trends and Challenges in Biosimilar Adoption - Biosimilars 2026 (France)
- Immunogenicity Assessment and Risk Management - Biosimilars 2026 (France)
- Industrial Biotech & Smart Biofactories - Biotechnology- 2025 (France)
- Industrial Biotechnology - Biotechnology 2025 (Spain)
- Industrial Scale-Up and Bioprocessing - Biotechnology 2025 (Spain)
- Interchangeability and Substitution Policies - Biosimilars 2026 (France)
- Manufacturing and Quality Control of Biosimilars - Biosimilars 2026 (France)
- Marine Biotechnology - Biotechnology 2025 (Spain)
- Microbial Biotechnology - Biotechnology 2025 (Spain)
- Nanotechnology in Medicine - Biotechnology- 2025 (France)
- Patient and Physician Perspectives on Biosimilar Use - Biosimilars 2026 (France)
- Personalized Nutrition & Gut Microbiome - Biotechnology- 2025 (France)
- Pharmacovigilance and Post-Marketing Surveillance - Biosimilars 2026 (France)
- Quantum Computing in Biotech - Biotechnology- 2025 (France)
- Regulatory Pathways and Global Harmonization - Biosimilars 2026 (France)
- Smart Biomanufacturing - Biotechnology- 2025 (France)
- Stem Cell and Regenerative Medicine - Biotechnology 2025 (Spain)
- Sustainable Biotech Innovations - Biotechnology- 2025 (France)
- Synthetic Biology and Bioengineering - Biotechnology 2025 (Spain)
- Synthetic Biology: Reprogramming Life - Biotechnology- 2025 (France)
- The Future of Biotech Startups - Biotechnology- 2025 (France)
- Vaccine Development and Immunotherapy - Biotechnology 2025 (Spain)